<DOC>
	<DOC>NCT01028729</DOC>
	<brief_summary>This single arm study will assess the safety and efficacy of Endostar combined with chemotherapy (Gemcitabine plus Platinum-based chemotherapy) followed by Endostar maintenance therapy in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description>All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression. Efficacy will be evaluated every two cycles.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Histological or cytological diagnosis of inoperable stage IIIB/IV NSCLC At least one measurable lesion Age of 1875 years Life expectancy &gt; 3 months ECOG performance status 02 Adequate hematologic, renal, and hepatic function Prior systemic chemotherapy for NSCLC Evidence of any unstable diseases (serious infection, grade 4 hypertension, unstable angina, congestive heartfailure, compromised renal or hepatic function, nonhealing wound or bone fracture) Concurrent anticoagulation therapy Evidence of bleeding diathesis or coagulopathy Pregnant or lactating women Allergic to E.coli preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>